Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
3.430
+0.080 (2.39%)
Apr 17, 2026, 9:45 AM EDT - Market open
Editas Medicine Revenue
In the year 2025, Editas Medicine had annual revenue of $40.52M with 25.39% growth. Editas Medicine had revenue of $24.74M in the quarter ending December 31, 2025, a decrease of -19.16%.
Revenue (ttm)
$40.52M
Revenue Growth
+25.40%
P/S Ratio
8.09
Revenue / Employee
$465,747
Employees
87
Market Cap
335.70M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 40.52M | 8.21M | 25.39% |
| Dec 31, 2024 | 32.31M | -45.81M | -58.64% |
| Dec 31, 2023 | 78.12M | 58.41M | 296.32% |
| Dec 31, 2022 | 19.71M | -5.83M | -22.83% |
| Dec 31, 2021 | 25.54M | -65.19M | -71.85% |
| Dec 31, 2020 | 90.73M | 70.20M | 341.93% |
| Dec 31, 2019 | 20.53M | -11.41M | -35.71% |
| Dec 31, 2018 | 31.94M | 18.21M | 132.64% |
| Dec 31, 2017 | 13.73M | 7.68M | 126.80% |
| Dec 31, 2016 | 6.05M | 4.42M | 271.58% |
| Dec 31, 2015 | 1.63M | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 79.59M |
| Zentalis Pharmaceuticals | 26.87M |
| LENZ Therapeutics | 19.09M |
| Abeona Therapeutics | 5.82M |
| AC Immune | 4.51M |
| Surrozen | 3.48M |
EDIT News
- 21 days ago - Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference - GlobeNewsWire
- 5 weeks ago - Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates - GlobeNewsWire
- 7 weeks ago - Editas Medicine to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Genflow Biosciences PLC Announces Directorate Change - Accesswire
- 5 months ago - Editas Medicine Announces Third Quarter 2025 Results and Business Updates - GlobeNewsWire
- 5 months ago - Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 - GlobeNewsWire
- 6 months ago - Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress - GlobeNewsWire
- 6 months ago - Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences - GlobeNewsWire